NasdaqGM - Nasdaq Real Time Price ? USD Applied Therapeutics, Inc. (APLT) Follow Compare 9.65 +0.02 (+0.21%) At close: November 6 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California. A live webcast for this event will be accessible on the Events page under the I GlobeNewswire ? yesterday APLT +0.21% Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? 8 days ago APLT +0.21% Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year? Here is how Applied Therapeutics Inc. (APLT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year. Zacks ? 8 days ago APLT +0.21% AXNX Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year? Here is how Applied Therapeutics Inc. (APLT) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year. Zacks ? 27 days ago APLT +0.21% CCLD Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year? Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year. Zacks ? last month APLT +0.21% CAH All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? last month APLT +0.21% APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia. Zacks ? last month APLT +0.21% Why Applied Therapeutics Stock Is Skyrocketing Today Investors are cheering good news from the FDA. Motley Fool ? last month APLT +0.21% Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug On Wednesday, Applied Therapeutics, Inc. (NASDAQ:APLT) stock traded higher with a session volume of 31.75 million, compared to an average volume of 1.26 million, according to data from Benzinga Pro. The company announced an update on the ongoing New Drug Application (NDA) review of govorestat for Classic Galactosemia. Galactosemia is an inherited metabolic disorder that makes the body unable to process a sugar called galactose. Also Read: Why Is Rare Disease-Focused Applied Therapeutics Stock Tr Benzinga ? last month APLT +0.21% Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia - Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of November 28, 2024 NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced an update GlobeNewswire ? last month APLT +0.21% Applied Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the company will participate in the following upcoming investor conferences: Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45 p.m. ET in New York, NY2024 Cantor Global Healthca GlobeNewswire ? 2 months ago APLT +0.21% Applied Therapeutics Reports Second Quarter 2024 Financial Results NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for the treatment of Classic Galactosemia tentatively scheduled for October 9, 2024Company aligned with the Neurology I Division on plans to submit an NDA under Accelerated Approval for govorestat for the tr GlobeNewswire ? 2 months ago APLT +0.21% Applied Therapeutics, Inc. (NASDAQ:APLT): When Will It Breakeven? Applied Therapeutics, Inc. ( NASDAQ:APLT ) is possibly approaching a major achievement in its business, so we would... Simply Wall St. ? 2 months ago APLT +0.21% Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside William Blair initiated coverage on Applied Therapeutics Inc. (NASDAQ:APLT), a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. The analyst says, “Applied Therapeutics is an under-the-radar company developing a nice mix of therapeutics targeting rare diseases and some larger indications with potential for several major value inflections over the next 12 months.” In April, the FDA extended the review period for Applied The Benzinga ? 3 months ago APLT +0.21% Applied Therapeutics Added to Russell 3000? Index NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was added to the Russell 3000? Index, effective after the U.S. market closed on June 28, 2024, as part of the 2024 Russell indexes annual reconstitution. “The addition of Applied to the Russell 3000? index under GlobeNewswire ? 4 months ago APLT +0.21% Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now? We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has […] Insider Monkey ? 4 months ago APLT +0.21% Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Applied Therapeutics... Simply Wall St. ? 4 months ago APLT +0.21% Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ... Exploring the Financial Landscape and Future Prospects Amidst Regulatory Advances GuruFocus.com ? 5 months ago APLT +0.21% Applied Therapeutics Reports First Quarter 2024 Financial Results Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025Company discussing potential NDA submission under Accelerated Approval for govorestat for treatment of SORD Deficiency with Neurology I Division of FDA NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biop GlobeNewswire ? 5 months ago APLT +0.21% Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 4:35 p.m. ET in New York, New York. A live webcast for this event will be accessible on the Even GlobeNewswire ? 5 months ago APLT +0.21% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return APLT S&P 500 YTD +188.06% +24.30% 1-Year +307.17% +36.04% 3-Year -39.00% +26.22%
